A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function
Status:
Completed
Trial end date:
2023-08-18
Target enrollment:
Participant gender:
Summary
Evaluate the pharmacokinetic differences of the main metabolite 116-N1 of JT001 in subjects
with mild and moderate liver function impairment and those with normal liver function,
providing a basis for formulating clinical medication plans for patients with liver function
impairment;